Influenza virus vaccines and uses thereof

Patent metadata

Field	Value
Publication number	US-9051359-B2
Application number	US-75039310-A
Country	US
Kind code	B2
Filing date	Mar 30, 2010
Priority date	Mar 30, 2009
Publication date	Jun 9, 2015
Grant date	Jun 9, 2015

Abstract

Provided herein are influenza hemagglutinin stem domain polypeptides, compositions comprising the same, vaccines comprising the same and methods of their use.

First claim

What is claimed is:

1. A vaccine comprising a polypeptide, wherein said polypeptide comprises:
a. an influenza hemagglutinin HA1 domain that comprises an HA1 N-terminal stem segment covalently linked to a linker of 1 to 50 heterologous residues that is in turn covalently linked to an HA1 C-terminal stem segment; said HA1 domain in tertiary or quaternary association with
b. an influenza hemagglutinin HA2 domain, and

wherein the vaccine induces antibodies which are cross-reactive among HA subtypes.

2. The vaccine of claim 1 , wherein in said polypeptide the HA1 domains contact the HA2 domain.

3. The vaccine of claim 1 , wherein in said polypeptide the HA1 C-terminal stem segment is covalently linked to the HA2 domain.

4. The vaccine of claim 1 , wherein the polypeptide in said vaccine has a tertiary or quaternary structure having 0-5 {acute over (Å)} RMS deviation from the tertiary or quaternary structure of the corresponding polypeptide of 1RUZ.

5. The vaccine of claim 1 , wherein the polypeptide in said vaccine selectively binds neutralizing antiserum capable of binding an influenza hemagglutinin.

6. The vaccine of claim 1 , wherein the polypeptide in said vaccine lacks an influenza globular domain.

7. The vaccine of claim 1 , wherein in said polypeptide (i) the amino acid sequences of the HA1 domains are at least 70%, 75%, 80%, 85%, 90%, 95%, 96% or 98% identical to the amino acid sequences of the corresponding domains of an HA1 from an H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15 or H16 influenza A virus; or (ii) the amino acid sequence of the HA2 domain is at least 70%, 75%, 80%, 85%, 90%, 95%, 96% or 98% identical to the amino acid sequence of an HA2 from an H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15 or H16 influenza A virus.

8. The vaccine of claim 1 , wherein in said polypeptide (i) the amino acid sequence of the HA2 domain is at least 70%, 75%, 80%, 85%, 90%, 95%, 96% or 98% identical to the amino acid sequence of an HA2 from an influenza B virus; or (ii). the amino acid sequences of the HA1 domains are at least 70%, 75%, 80%, 85%, 90%, 95%, 96% or 98% identical to the amino acid sequences of the corresponding domains of an HA1 from influenza B virus.

9. The vaccine of claim 1 , wherein in said polypeptide the HA1 N-terminal stem segment comprises a cysteine residue covalently linked to a cysteine residue of the HA1 C-terminal stem segment via a disulfide bridge.

10. The vaccine of claim 1 , wherein in said polypeptide the HA1 N-terminal stem segment comprises the amino acid sequence A 17 -A 18 -(Xaa) n -A 38 (SEQ ID NO:146), wherein
A 17 is Y or H;
A 18 is H, L, or Q;
(Xaa) n represents a sequence of 18-20 amino acid residues; and
A 38 is H, S, Q, T or N.

11. The vaccine of claim 1 , wherein in said polypeptide the HA1 C-terminal stem segment comprises the amino acid sequence A 291 -A 292 , wherein
A 291 is T, S, N, D, P or K; and
A 292 is L, M, K or R.

12. The vaccine of claim 1 , wherein in said polypeptide the HA2 domain comprises the amino acid sequence A 18 -A 19 -A 20 -A 21 , wherein
A 18 is V or I;
A 19 is D, N or A;
A 20 is G, and
A 21 is W.

13. The vaccine of claim 1 , wherein in said polypeptide the HA2 domain comprises the amino acid sequence A 38 -A 39 -A 40 -A 41 -A 42 -A 43 -A 44 -A 45 -A 46 -A 47 -A 48 -A 49 -A 50 -A 51 -A 52 -A 53 -A 54 -A 55 -A 56 (SEQ ID NO:149), wherein
A 38 is K, Q, R, L or Y;
A 39 is any amino acid residue;
A 40 is any amino acid residue;
A 41 is T;
A 42 is Q;
A 43 is any amino acid residue;
A 44 is A;
A 45 is I;
A 46 is D;
A 47 is any amino acid residue;
A 48 is I, V or M;
A 49 is T, Q or N;
A 50 is any amino acid residue;
A 51 is K;
A 52 is V or L;
A 53 is N;
A 54 is any amino acid residue;
A 55 is V, I or L; and
A 56 is V or I.

14. The vaccine of claim 1 , wherein in said polypeptide said linker is of 1 to 40, 1 to 30 residues, 1 to 20 residues, 1 to 10 residues, 1 to 5 residues, 1 to 4 residues, 1 to 3 residues, 1 to 2 residues or 1 residue.

15. The vaccine of claim 1 , wherein in said polypeptide said linker is GG, PG, GGG, GGGG (SEQ ID NO:319), GGGGG (SEQ ID NO:320), ITPNGSIPNDKPFQNVNKITYGA (SEQ ID NO:165), or NAS.

16. A vaccine comprising a virus comprising a genome engineered to express a nucleic acid encoding a polypeptide, wherein said polypeptide comprises:
a. an influenza hemagglutinin HA1 domain that comprises an HA1 N-terminal stem segment covalently linked to a linker of 1 to 50 heterologous residues that is in turn covalently linked to an HA1 C-terminal stem segment; said HA1 domain in tertiary or quaternary association with
b. an influenza hemagglutinin HA2 domain, and

wherein the vaccine induces antibodies which are cross-reactive among HA subtypes.

17. A vaccine comprising a virus comprising a polypeptide, wherein said polypeptide comprises:
a. an influenza hemagglutinin HA1 domain that comprises an HA1 N-terminal stem segment covalently linked to a linker of 1 to 50 heterologous residues that is in turn covalently linked to an HA1 C-terminal stem segment; said HA1 domain in tertiary or quaternary association with
b. an influenza hemagglutinin HA2 domain, and

wherein the vaccine induces antibodies which are cross-reactive among HA subtypes.

18. The vaccine of claim 16 or 17 , wherein the virus is an influenza virus, a Newcastle disease virus (NDV), a vaccinia virus, an adenovirus, an adeno-associated virus (AAV), or a retrovirus.

19. The vaccine of claim 17 , wherein said virus is inactivated or split.

20. The vaccine of claim 1 , further comprising an adjuvant.

21. A method of immunizing a human subject comprising administering to the subject an effective amount of the vaccine of claim 1 .

22. A method of preventing an influenza virus disease comprising administering to a human subject an effective amount of the vaccine of claim 1 .

23. A method of treating an influenza virus infection or an influenza virus disease comprising administering to a human subject an effective amount of the vaccine of claim 1 .

24. The vaccine of claim 1 , wherein in said polypeptide (i) the amino acid sequence of the HA1 N-terminal stem segment consists of amino acid residues corresponding to the N-terminal amino acid of HA1 through the cysteine residue in the HA1 N-terminal stem segment that forms or is capable of forming a disulfide bond with a cysteine residue in an HA1 C-terminal stem segment; and (ii) the amino acid sequence of the HA1 C-terminal stem segment consists of amino acid residues corresponding to the cysteine residue in the HA1 C-terminal stem segment that forms or is capable of forming a disulfide bond with a cysteine residue in an HA1 N-terminal stem segment through the C-terminal amino acid of the HA1 domain.

25. The vaccine of claim 16 , wherein said polypeptide lacks an influenza globular domain.

26. The vaccine of claim 16 , wherein in said polypeptide said linker is GG, PG, GGG, GGGG (SEQ ID NO:319), GGGGG (SEQ ID NO:320), ITPNGSIPNDKPFQNVNKITYGA (SEQ ID NO:165), or NAS.

27. The vaccine of claim 16 , wherein in said polypeptide (i) the amino acid sequence of the HA1 N-terminal stem segment consists of amino acid residues corresponding to the N-terminal amino acid of HA1 through the cysteine residue in the HA1 N-terminal stem segment that forms or is capable of fo

Assignees

• Garcia-Sastre Adolfo
• Lowen Anice C
• Palese Peter
• Steel John F
• Icahn School Med Mount Sinai

Inventors

• Garcia-Sastre Adolfo
• Lowen Anice C
• Palese Peter
• Steel John F

Classifications

• C12N2760/16134

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• A61K2039/545

  characterised by the dose, timing or administration schedule · CPC title

• A61K2039/58

  raising an immune response against a target which is not the antigen used for immunisation · CPC title

• A61K39/145 Primary

  Orthomyxoviridae, e.g. influenza virus · CPC title

• C12N2760/16222

  New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title